Latest Monoclonal antibody therapy Stories
NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis http://www.reportlinker.com/p0166816/The-Future-of-Monoclonal-Antibodies---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html Summary The author has released its latest research "The Future of Monoclonal...
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight http://www.reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Competitive-Landscape-and-Pipeline-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent...
There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.Cetuximab (Erbitux) is a monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). It is widely used to treat colorectal cancer and head and neck cancer. Although cetuximab and other EGFR inhibitors are associated with a...
LELYSTAD, The Netherlands, April 6 /PRNewswire/ -- Today, Pepscan reports that it has achieved a major scientific breakthrough through the use of its CLIPS-based synthetic peptide immunogen technology. By constructing synthetic 3D mimics of the ligand binding-site on CXCR7 it has induced functional antibodies against the formerly intractable GPCR target CXCR7. CXCR7 is novel therapeutic target thought to be involved in tumor angiogenesis. "We are proud and confident with achieving...
In hopes of more fully tapping the libraries' potential, a group of Scripps Research Institute scientists, led by Scripps Research President Richard A. Lerner, M.D., has for the first time developed a new screening technique that enables antibody screening against equally massive libraries of targets. This technique makes it possible to accelerate searches for new treatments against cancer and other diseases.The work is being reported in this week's Early Edition of the journal Proceedings of...
BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody...
MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,435,803 was issued today covering the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on...
IBC Life Sciences announces the 19th Annual International Antibody Engineering Conference will return to San Diego, California on December 7-11, 2008. This meeting serves as the annual forum of the antibody and protein engineering communities, providing insights to drive the future of antibody engineering and the development of immunotherapeutics. This year's Keynote speakers have been leading pioneers in this field since its beginning, having contributed many of the advancements that...
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 http://www.reportlinker.com/p096392/Therapeutic-Monoclonal-Antibodies-Report-2008-2023.html This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure...
In 2007, total global monoclonal antibody sales reached $26 billion and are forecast to almost double by 2013. Traditionally, the 'big five' monoclonal antibodies have dominated the market, accounting for almost 80% of sales in 2007. However, Datamonitor has identified an emerging group of eight, each of which will achieve annual sales of at least $500 million between 2007-2013. Segmenting the prescription pharmaceutical market by molecule type (small molecule, therapeutic protein,...
